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INTRODUCTION 
Fatty liver degeneration, also termed hepatic ste-
atosis (HS), is defined as hepatic lipid accumulation 
affecting more than 5% of the total weight of the or-
gan (1). Histologically, there are two forms of hepat-
ic steatosis termed macrovesicular and microvesic-
ular (2). Macrovesicular steatosis is characterized 
by one large vacuole containing triglycerides, which 
displaces the cell’s nucleus to its periphery, whereas 
microvesicular steatosis is characterized by multi-
ple miniscule lipid droplets in the hepatic cytoplasm, 
giving it foamy cytoplasm. 
In adults, fatty liver degeneration is typically as-
sociated with excessive alcohol intake as in alcohol-
ic fatty liver disease (AFLD) or with sedentary life-
style and high-calorie diet as in primary non-alco-
holic fatty liver disease (NAFLD) (3). Even though 
obesity is the leading cause of NAFLD in adults, the 
same correlation cannot be established for pediatric 
patients (4). In children fatty liver disease can also be 
caused by viral disease, inherent metabolic disease 
of lipid and carbohydrate metabolism, Wilson’s dis-
ease, α1-antitrypsin deficiency, autoimmune disease, 
drugs, toxins, severe malnutrition or feeding disor-
ders in which case NAFLD is termed secondary (5). 
NAFLD is an inclusive term used to describe a whole 
spectrum of diseases. Based on histology, NAFLD is 
further classified as non-alcoholic fatty liver (NAFL) 
or simple steatosis, non-alcoholic steatohepatitis 
(NASH) when inflammation is present, and NAFLD 
with fibrosis when periportal, portal or sinusoidal fi-
brosis is present (3). 
EPIDEMIOLOGY
Because of its close association with obesity, NA-
FLD has become the most common chronic liver 
disease in both adults and children. Because the de-
finitive diagnosis of NAFLD in children is reached 
by performing liver histology (1,3), the exact preva-
lence and incidence of the disease are unknown. Ac-
cording to a Schwimmer J et al. (6), who made a ret-
rospective review of 742 children between 2 and 19 
years of age who had an autopsy from 1993 to 2003, 
fatty liver was present in 13% of the subjects. After 
adjusting for age, gender, race and ethnicity, the au-
thors estimated the prevalence to be 9.6%, the high-
est being for 15 to 19 years of age (17.3%) and obese 
children (38%).
A clear rise in prevalence meeting the rise of obe-
sity during the last decade was elucidated by Welsch 
J. et al (7), who performed a cross-sectional retro-
spective study of the data from 12714 children be-
tween 12-19 years of age from the National Health 
and Examination Survey from 1988-1994 and 2007-
2010. Using screening criteria for diagnosis of possi-
ble NAFLD (BMI > 85th percentile and alanine ami-
notransferase level >25.8 U/L for boys and >22.1 U/L 
for girls), the authors concluded that the prevalence 
of suspected NAFLD had risen twice over the inves-
tigated period, affecting half of the obese patient and 
10.7% of all the patients included in the study.
Although the prognosis of pediatric NAFLD re-
mains uncertain, given that it is by definition an ear-
ly onset disease, it may represent an aggressive dis-
ease phenotype.
ABSTRACT
Fatty liver degeneration, also termed hepatic steatosis, is a condition in which lipids accumulate in the 
hepatocytes causing cellular dysfunction and eventually cell death. Hepatic steatosis is diagnosed histologically 
when liver fat exceeds more than 5% of the liver weight. In adults, fatty liver degeneration is typically associated 
with excessive alcohol intake as in alcoholic fatty liver disease or with sedentary lifestyle and high-calorie diet as in 
non-alcoholic fatty liver disease (NAFLD). With the rise of obesity in recent decades, fatty liver disease has become 
the leading cause of chronic liver disease, not only in adults but in children as well. Besides liver disease, obesity is 
associated with several conditions among which is obstructive sleep apnea. 
The aim of this article is to review the pathogenesis of fatty liver degeneration focusing on NAFLD and its 
relationship with obstructive sleep apnea in children. 
Keywords: pediatric fatty liver, pathogenesis, obstructive sleep apnea
Fatty Liver Degeneration in Children: Association with Obstructive Sleep Apnea
96
lead to lipid peroxidation in the liver, and the levels 
of lipid peroxidation are related to the severity of hy-
poxia (12).
The link between OSA and NAFLD has been rec-
ognized not only in adults (13) but in children as well 
(14,15). The prevalence of NAFLD in pediatric pa-
tients suffering from OSA was described by Khei-
randish-Gozal et al. (16), who studied 518 consecu-
tive snoring children 4 to 17 years of age who were 
being evaluated for habitual snoring and suspected 
OSA. Among the 142 overweight/obese children, 46 
had elevated LFT levels (32.4%); of these children, 42 
had OSA (91.3%). In contrast, OSA was present in 
only 71.8% of Ob children without elevated LFT lev-
el (p <0.01).
Regarding treatment, in 2018, Sundaran et al. 
(17) studied 9 pediatric patients with biopsy proven 
NAFLD before and after treatment with continuous 
positive airway pressure (CPAP) including laborato-
ry testing and F(2)-isoprostanes – a marker of oxida-
tive stress, compared to a control group. The authors 
reported that at baseline the target group had severe 
OSA, metabolic syndrome, elevated aminotransfer-
ases and high F(2)-isoprostanes. After treatment du-
ration of 89 ± 62 days with adherence of 296 minutes/
night and 73% of nights prescribed, the treatment 
group showed improvement not only in obstruc-
tive sleep apnea/hypoxia severity but also in alanine 
aminotransferase level, metabolic syndrome mark-
ers and F(2)-isoprostanes. Unfortunately, the sample 
size of the study was a limiting factor to reaching sta-
tistical significance.
CONCLUSION
The emerging global obesity epidemic has made 
pediatric NAFLD one of the most common chron-
ic liver diseases in childhood, with estimates of 9.6% 
of children being affected. Because NAFLD is part of 
the spectrum of obesity related diseases, care should 
be taken to consider co-existing conditions which 
may be associated with NAFLD progression such as 
OSA. Based on the current evidence that the risk of 
NAFLD is higher in habitually snoring obese chil-
dren and that CPAP therapy is associated with im-
provement in surrogate markers for disease severi-
ty, obese children with OSA may benefit from coor-
dinated treatment and evaluation of ENT specialists 
and gastroenterologists.
PATHOGENESIS
Currently, the pathogenesis of NAFLD is defined 
by multifactorial interaction, leading to hepatic tri-
glyceride accumulation, termed the “multiple hit” 
hypothesis (8). At disease onset, genetic susceptibil-
ity, epigenetic mechanisms, sedentary lifestyle and 
hypercaloric diets lead to increased delivery of carbo-
hydrates and free fatty acids (FFAs) to the organism. 
Under the effect of insulin, carbohydrates are used to 
form acetyl-coenzyme A, which is used in lipogen-
esis in the liver with the resulting FFAs transported 
to the adipose tissue for storage. In the adipocytes, 
insulin causes inhibition of lipolysis and induces es-
terification of FFAs to triacylglycerol (TAG), which is 
stored in the adipocytes. 
Over time, insulin resistance (IR) ensues by lipid 
accumulation interfering with insulin receptor phos-
phorylation which leads to unsuppressed lipolysis in 
the adipocytes and release of FFAs to the liver. He-
patocytes also experience IR, which leads to reduced 
suppression of gluconeogenesis but preserved stim-
ulation of lipogenesis. The accumulated lipids in the 
hepatocytes are mainly in the form of TAG, which 
can be considered a protective mechanism because 
TAG is not hepatotoxic unlike FFAs. When lipid ef-
flux exceeds the ability of the liver for triglyceride 
storage, FFAs exhibit their lipotoxicity, which pre-
disposes the hepatic cells to “secondary hits” such as 
pro-inflammatory cytokines, oxidative stress, and 
mitochondrial dysfunction (9,10).
Relationship Between Obstructive Sleep Apnea 
and NAFLD in Childhood
An example of “secondary hit”, which induces 
a more severe form of NAFLD, is obstructive sleep 
apnea (OSA). Patients with OSA experience epi-
sodes of recurrent upper-airway obstruction during 
sleep, leading to hypoxia alternating with normox-
ia (chronic intermittent hypoxia - CIH), resembling 
the pathophysiology of ischemia/reperfusion inju-
ry. The condition is associated with all manifesta-
tions of metabolic syndrome, including obesity and 
NASH. The direct association of CIH and NASH was 
documented by Savransky et al. (11) using mice on 
high-cholesterol, high-fat diet for 6 months and si-
multaneously exposing them to CIH which resulted 
in raised ALT and AST levels, inflammatory infiltra-
tion and fibrosis of the liver, and significant increases 
in levels of pro-inflammatory cytokines IL-1β, IL-6, 
and MIP-2 in liver tissue, whereas control animals on 
the same diet exhibited liver steatosis without any ev-
idence of inflammation. Murine models on regular 
diet exposed to different CIH have shown that both 
severe CIH with an inspired oxygen nadir of 5% and 
moderate CIH with an inspired oxygen nadir of 10% 
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